▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2975 by analyst upside · 2026-11-12
CI
The Cigna Group
Healthcare · Market Cap $79B · P/E 13.4x
ANALYST PRICE TARGET
+13.8%
implied upside to consensus target
Current Price $301.45
Consensus Target $343.08
Bull Target $400.0
Bear Target $288.0
Analysts Covering 25
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
12
Hold
8
Sell
0
52-Week Low $257.85
52-Week High $318.05
YTD Return +9.8%
FUNDAMENTALS
Market Cap $79B
P/E Ratio (TTM) 13.4x
Forward P/E 9.0x
EPS (TTM) $22.55
PEG Ratio 0.83
Dividend Yield 2.06%
Revenue (TTM) $286.3B
Profit Margin 2.1%
52-WEEK RANGE
52-Week Low $257.85
52-Week High $318.05
Current Price $301.45
Bear Target $288.0
Bull Target $400.0
● Now $301.45 ● Target $343.08
TRADING DATA
Avg Volume 1.6M
YTD Return +9.8%
Analyst Count 25
Consensus Buy
Upside to Target +13.8%
Last Updated 2026-11-12

ANALYST SUMMARY

The Cigna Group (CI) is currently trading at $301.45 with a Wall Street consensus price target of $343.08, implying potential upside of 13.8% over the next 12 months. 25 analysts currently cover CI, with a consensus rating of Buy - 68% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $400.0, while the most cautious has a target of $288.0.

CI operates in the Healthcare sector with a market capitalisation of $79B. The stock is up 9.8% year-to-date and is currently trading near the upper end of its 52-week range of $257.85 – $318.05.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

COR +9.0%
Cencora, Inc.
$67B · P/E 19.4x · Buy
BSX +9.9%
Boston Scientific Corporation
$65B · P/E 18.9x · Buy
REGN +1.9%
Regeneron Pharmaceuticals, Inc.
$99B · P/E 20.2x · Buy
ELV +12.3%
Elevance Health, Inc.
$93B · P/E 18.2x · Buy
ARGX +17.4%
argenx SE
$61B · P/E 33.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group - Reiterated
In-Line → In-Line 2026-11-06 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-11-06 62% win rate (8 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2026-11-06 40% win rate (10 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-10-02 14% win rate (7 calls)
RBC Capital reit
Outperform → Outperform 2026-10-01 Building track record
Jefferies ↓ Downgrade
Buy → Hold 2026-08-04 50% win rate (6 calls)
Raymond James ↓ Downgrade
Strong Buy → Outperform 2026-08-03 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-07-31 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
62
out of 100
Coverage depth
25/30
Consensus clarity
23/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →